Thomas D. C.
- Country
- Belgium
- Department
- 105602: Hematologie
Research Overview
- Efficacy of Ziftomenib Combined with Standard of Care Therapy in Patients with Untreated NPM1-Mutated or KMT2A-Rearranged Acute Myeloid Leukemia
- Phase 1 Study of JNJ-95804306 in Relapsed or Refractory AML, CLL, Higher‑Risk MDS, and SLL
- SAFE study: Stopping Antibiotics after 3 days for the treatment of FEbrile Neutropenia in Haematology patients, a randomized open-label non-inferiority trial
Data & Insights
Has run more than one trial at 68 of 269 partner sites.
Specializations
Hematological Conditions
This investigator specializes in treating patients with febrile neutropenia, focusing particularly on optimizing antibiotic treatment protocols in hematology patients.
- Blood Disorders Management
- Neutropenia Treatment
- Fever Management in Immunocompromised Patients
The investigator's work addresses critical aspects of infection control in hematology patients requiring antibiotic intervention.
Infection Control
The investigator focuses on developing innovative approaches to antibiotic treatment strategies, particularly in the context of managing infections in immunocompromised patients.
- Antimicrobial Therapy Optimization
- Treatment Duration Assessment
- Broad-spectrum Antibiotic Management
Their expertise extends to evaluating the effectiveness of short-duration antibiotic treatments in high-risk patient populations.
Clinical Safety Assessment
The investigator evaluates treatment safety protocols for hematology patients, with particular emphasis on determining optimal antibiotic treatment durations.
- Risk Assessment in Neutropenic Patients
- Treatment Duration Optimization
- Patient Safety Monitoring
Their work contributes to establishing evidence-based guidelines for antibiotic treatment in immunocompromised patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.